Evidence map›Paper›PMID 42747429›Full record

ArticleAntimicrobial agents and chemotherapy2026

Mechanistic blockade of RSV infection by a pre-F targeting single-domain antibody-Fc fusion protein.

Shuang Liu, Xiran Qiu, Shiyu Guo, Liying Wang, Hui Shen, Maomao An

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuang LiuDepartment of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Xiran QiuDepartment of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Shiyu GuoResearch and Technology Development Center, Starmab Biologics (Suzhou) Co., Ltd., Shanghai, China.
Liying WangDepartment of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Hui ShenDepartment of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0002-7456-5536
Maomao AnDepartment of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0003-2872-9074

Funding

National Natural Science Foundation of China 82173864National Natural Science Foundation of China 82572648
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a primary cause of acute lower respiratory tract infections in children and the elderly. Despite its clinical impact, effective prophylactic options for RSV remain limited. The prefusion conformation of the RSV fusion (F) protein is a critical target for neutralizing antibodies; however, the specific roles of prefusion versus postfusion states in triggering inflammatory responses have remained unclear. We report the development of Hu3F5, a novel prefusion F-specific single-domain antibody-Fc fusion protein. Hu3F5 demonstrates exceptional neutralizing activity

Indexed as

Antiviral AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsSingle-Domain AntibodiesViral Fusion ProteinsAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSingle-Domain AntibodiesViral Fusion Proteinsconformational changeFc-fusion proteininfectionRSVsingle domain antibody

Identifiers

PMID42747429
PMCPMC13689173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.